drugset
drugset / Trial / NCT06387966

A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects

NCT06387966 ↗

Phase 1 Completed 40 enrolled Chengdu Zenitar Biomedical Technology Co., Ltd
RandomizedSequentialQuadruple-blindOther

Summary

Evaluate the safety , tolerability and pharmacokinetics of Flonoltinib Maleate tablets in a single increasing dose oral administered to healthy adult Chinese subjects.Subjects will divide into experimental group and placebo group, conduct single oral administration safety and tolerability test group by group.

Timeline

Start
2024-03-18
Primary completion
2024-08-15
Completion
2024-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Flonoltinib Unknown 25 mg Oral
Subject Flonoltinib Unknown 50 mg Oral
Subject Flonoltinib Unknown 100 mg Oral
Subject Flonoltinib Unknown 150 mg Oral
Subject Flonoltinib Unknown 200 mg Oral

Indications

No indication recorded.